Are Wall Street Analysts Bullish on Oracle Stock?
Shares of the Austin, Texas-based company have significantly outperformed the broader market over the past 52 weeks. ORCL stock has climbed nearly 100% over this time frame, while the broader S&P 500 Index ($SPX) has gained 21.5%. In addition, shares of Oracle have surged 53.4% on a YTD basis, compared to SPX's 7.1% rise.
More News from Barchart
Palantir's Free Cash Flow Margins and Forecasts Rise - Where This Leaves PLTR Stock
Cathie Wood is Buying Figma Stock with Both Hands. Should You Buy This Hot IPO, Too?
Can SoundHound's Q2 Results Send the Stock Soaring on August 7?
Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now!
Looking closer, the software maker stock has also outpaced the Technology Select Sector SPDR Fund's (XLK) 31.4% return over the past 52 weeks.
Shares of Oracle soared 13.3% following its Q4 2025 results on Jun. 11. The company reported adjusted EPS of $1.70 and revenue of $15.9 billion, topping forecasts. Oracle raised its fiscal 2026 revenue forecast to at least $67 billion, implying 16.7% growth, driven by accelerating demand for Oracle Cloud Infrastructure (OCI) and AI workloads. The management highlighted that total cloud growth is expected to rise over 40% in 2026.
For the fiscal year ending in May 2026, analysts expect ORCL's EPS to grow 20.7% year-over-year to $5.31. The company's earnings surprise history is mixed. It beat or met the consensus estimates in three of the last four quarters while missing on another occasion.
Among the 36 analysts covering the stock, the consensus rating is a 'Strong Buy.' That's based on 25 'Strong Buys,' one 'Moderate Buy' rating, and 10 'Holds.'
This configuration is more bullish than three months ago, with 20 'Strong Buy' ratings on the stock.
On Aug. 5, BofA analyst Brad Sills raised Oracle's price target to $295 while maintaining a 'Neutral" rating, citing strong capex guidance from Microsoft and Meta as positive signals for AI infrastructure demand, benefiting Oracle as a key player in the AI cycle.
As of writing, the stock is trading above the mean price target of $240.57. The Street-high price target of $315 implies a potential upside of 23.2% from the current price levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
17 minutes ago
- Business Journals
Define Body & Mind founder to build wellness-focused apartment community in Energy Corridor
Expand Houston-based Define Living plans to build a new 388-unit apartment building in the Energy Corridor. Courtesy of Define Living
Yahoo
28 minutes ago
- Yahoo
S&P 500 Gains & Losses Today: UFC Parent TKO Soars, Intel Stock Rises; Hershey Drops
Key Takeaways The S&P 500 slipped 0.3% on Monday, Aug. 11, 2025, ahead of a key inflation report on Tuesday and as President Trump pushed back the deadline for higher China tariffs. TKO Holdings shares soared after the newly combined Paramount Skydance said it acquired exclusive broadcasting rights for the sports company's UFC mixed martial arts franchise. Intel's stock also rose. Hershey shares, which have been pressured by elevated cocoa prices, declined as futures prices for the key ingredient of chocolate pushed even higher.U.S. equities indexes moved lower to kick off the trading week ahead of Tuesday's anticipated release of July Consumer Price Index data, which could factor into the Federal Reserve's upcoming interest-rate decisions. Trade policy also remained in the spotlight, with President Donald Trump extending the deadline for higher tariffs on imports from China by an additional 90 days. The S&P 500 fell 0.3% on Monday. The Nasdaq was also down around 0.3%, receding from the record closing high posted at the end of last week. The Dow dropped roughly 0.5%. Read Investopedia's full coverage of today's trading here. Shares of TKO Group Holdings (TKO), owner of the Ultimate Fighting Championship franchise, surged more than 10% to notch the day's best performance in the S&P 500. The move highercame after the newly formed Paramount Skydance (PSKY) announced a seven-year deal for exclusive UFC broadcasting rights worth $7.7 billion. Paramount Skydance shares sank 3.7% on Monday, the third day of trading following the closing of the merger between Skydance Media and the former Paramount Global. China's Contemporary Amperex Technology, or CATL, said that it halted production at a key lithium mine following the expiration of the mine's permit. The expectation that a resulting downtick in lithium supply could provide some relief for the slumping price of the key battery component helped boost shares of other producers. Albemarle (ALB), the world's largest lithium producer, advanced 7%. Shares of video game maker Electronic Arts (EA) added 5.1% following positive comments from several research firms. Analysts at Oppenheimer discussed the successful beta test of EA's upcoming title Battlefield 6, noting polished and authentic gameplay as well the technical ability to manage a surge in players during the test without sacrificing the user experience. Meanwhile, analysts at D.A. Davidson lifted their price target on EA stock, although they struck a cautious tone about lofty Battlefield 6 targets and raised concerns about the growth trajectory of the company's American Football business, maintaining a "neutral" rating on the shares. Intel (INTC) shares gained 3.7% following reports that CEO Lip-Bu Tan was set to visit the White House after Trump called for his resignation in a social media post last week. The Wall Street Journal suggested that Tan could seek to improve the chipmaker's relationship with the Trump administration and possibly lay the groundwork for new deals. Shares of financial software provider Intuit (INTU) dropped 5.7%, the most of any S&P 500 stock on Monday. Analysts pointed to a number of headwinds for the company. Intuit's TurboTax Live platform, a service providing limited support for do-it-yourself tax filers and a key growth driver for the company, could face disruption from generative AI technologies, while the uncertain macroeconomic environment has raised concerns about the revenue Intuit generates from small and medium-sized businesses. Hershey (HSY) stock sank 4.8%. Shares of the chocolate maker have been pressured by elevated cocoa prices, and futures prices for the key ingredient jumped even higher Monday, reflecting concerns that dry conditions in West Africa could lead to softer crop production. Hershey said late last month that it would increase prices as it seeks to offset the cocoa-driven cost pressure. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Why Roivant Sciences Stock Was Slipping on Monday
Key Points The biotech published an earnings report that fell short of expectations. It whiffed on both the top and bottom lines. 10 stocks we like better than Roivant Sciences › Commercial-stage biotech Roivant Sciences (NASDAQ: ROIV) started the trading week with an earnings release. In retrospect, that might not have been the wisest move. Following Monday morning's unveiling of its fiscal first-quarter release, investors generally traded out of the stock. It had slid by more than 3% in late-session trading at a point when the S&P 500 index was only down marginally. Falling short Roivant reported that its revenue for the period was slightly under $2.2 billion, which was quite some distance down from the nearly $8 billion it reaped in the same quarter last year. The situation was hardly better on the bottom line, as the company flipped to a more than $223 million ($0.33 per share) generally accepted accounting principles (GAAP) net loss from the year-ago profit of $95 million. Compounding that, neither result met analyst expectations. The consensus pundit projection for revenue was far higher, at almost $7.7 billion, while that for net loss was narrower ($0.25). Roivant did not provide details for its financial line items either in its earnings release or the 10-Q quarterly-earnings statement it filed with the Securities and Exchange Commission (SEC); this somewhat black-box quality might have contributed to the negative investor reaction. An industry outlier Roivant is atypical even for the extremely varied biotech sector in that it divides its business into "vants" -- subsidiaries -- based on a specific medication or cluster of drugs. Over time, some of these have been sold to business partners in order to raise capital. Regarding that subject, Roivant said that it had cash, equivalents, restricted cash, and marketable securities amounting to roughly $4.5 billion. That was down from the nearly $4.9 billion in the year-ago quarter. Do the experts think Roivant Sciences is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Roivant Sciences make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,060% vs. just 182% for the S&P — that is beating the market by 877.59%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy. Why Roivant Sciences Stock Was Slipping on Monday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
